Navigation Links
Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results

PURCHASE, N.Y., May 8 /PRNewswire-FirstCall/ -- Nutrition 21, Inc. (Nasdaq: NXXI), the developer and marketer of nutritional supplements under the Iceland Health(R), Chromax(R), Advanced Memory Formula(TM) and Diabetes Essentials(TM) -- brands that help consumers manage blood sugar levels, improve cardiovascular health, enhance memory and reduce chronic joint pain, today announced financial results for the third quarter of fiscal year 2008 ended March 31, 2008.

For the quarter ended March 31, 2008, the company reported total revenues of $10.8 million compared to $15.8 million in the comparable quarter a year ago. The year-ago quarter included a large one-time sale of Selenomax(R) High Selenium Yeast -- without this sale, the year-ago revenues would have been $13.2 million.

The company reported a net loss of $8.2 million for the quarter ended March 31, 2008 or ($0.13) per fully diluted share compared to a loss of $2.2 million or ($0.04) per fully diluted share in the comparable quarter a year ago. Financial results for the quarter were impacted by approximately $3.2 million of one-time expenses, including a provision for inventory obsolescence within the retail business unit, a provision for possible settlements of outstanding litigations, and costs associated with the resignation of the former CEO.

At March 31, 2008, the company had $5.6 million in cash, investments and restricted cash compared to $9.5 million on December 31, 2007. For the quarter, net cash used in operating activities was ($2.4 million).

Total revenues for the nine months ended March 31, 2008 were $36.0 million compared to $29.6 million in the same period a year ago. The company's net loss for the nine months ended March 31, 2008 was $16.0 million, or $(0.26) per fully diluted share, compared to $11.0 million, or $(0.19) per fully diluted share, in the comparable period a year ago.

During the quarter the Company appointed Gerard Butler and Michael Fink as interim co-chief executive officers. Both Mr. Butler and Mr. Fink were executives at Prestige Brands Holdings, Inc., a marketer and distributor of brand name over-the-counter healthcare, personal care and household cleaning products sold throughout the U.S., Canada, and in certain international markets. They previously worked for Block Drug Company. They have extensive experience in the consumer and nutraceutical industry.

Peter Mann, a Director and consultant to the Company, said, "Nutrition 21 has reached an important inflexion point in its development. Over the past 18 months, the company has invested heavily in developing its formulas, its patent positions and its consumer business -- both in the retail and direct response business units. All of this accomplishment has come at a significant cost. We are now ready to begin reaping the fruits of that investment. Our new top management has been tasked with achieving positive EBITDA (a non-GAAP measure defined as net earnings before interest, taxes, depreciation and amortization) and positive cash flow while maintaining steady revenue growth. We're pleased with the progress already made after only six weeks and are optimistic that future financial results will show an immediate and significant improvement."

"Our strategic vision," Michael Fink, co-chief executive officer of Nutrition 21, Inc., said, "is to leverage the Company's significant expertise in the direct response business to more aggressively build the Iceland Health franchise. Over the next 12 months, we plan to support the Iceland Health business with strong marketing spends consistent with achieving profitability. Additionally, we plan to introduce new products into the direct response business. As these products prove successful in direct response, we will introduce them into retail distribution. We believe this strategy will generate greater efficiencies from the marketing dollars that we spend, enabling us to successfully create brand identity in a cost-effective manner."

Gerard Butler, co-chief executive officer of Nutrition 21, said, "Over the course of the next six months, we intend to re-brand all of our existing products in the food, mass and drug channels under the Iceland Health name. Iceland Health has developed a strong franchise with consumers over the years, and this represents a significant opportunity for our existing products to benefit from Iceland Health's reputation for quality and consumer loyalty. We believe this is another opportunity to leverage our marketing spend in a more efficient manner. Our expectation is to support the Iceland Health brand in direct and retail channels with strong marketing spending consistent with profitability."

"On another front," continued Mr. Butler, "in the future, we plan to expand our ingredient portfolio with unique formulations. Our customers have a large group of brand name products that feature our ingredients as 'value-added' components, including a number of brands that use our Chromax trademark on their labels. We expect to market our ingredients portfolio on a wider scale and attract more brand name products that can be enhanced by the addition of a Nutrition 21 ingredient."

Mr. Fink added, "With a strong focus on managing cost and increasing operating efficiencies, we expect to successfully drive our products through both the direct-to-market and the retail channels in the most cost-efficient manner with the goal of achieving profitability at the earliest possible date."

Mr. Mann concluded, "While it is the policy of Nutrition 21 not to provide detailed forward-looking financial guidance, the Company believes it is important for all investors to have reasonable visibility into the future outlook for the business. The Company expects that EBITDA will approach breakeven in the June 2008 quarter, while June quarter revenues are estimated to be in the same general range as the preceding quarter. Looking forward to the fiscal year ending June 30, 2009, the Company anticipates relatively stable revenues with consistently positive EBITDA."

Conference Call

The Company has scheduled a conference call to review the results of the quarter today (Thursday, May 8, 2008) at 8:30AM ET. Messrs. Mann, Fink, Butler and Kirschbaum will all participate in the call for Nutrition 21.

Participants can dial (866) 562-9910 or (706) 679-5064 to access the conference call, or can listen via a live Internet web cast, which can be found at A replay of the call is available by visiting for the next 30 days or by calling (800) 642-1687 or (706) 645-9291, access code 43095471, through May 11, 2008.

About Nutrition 21

Nutrition 21, Inc. (NASDAQ: NXXI), headquartered in Purchase, NY, is a nutritional bioscience company and the maker of chromium picolinate-based and omega-3 fish oil-based supplements with health benefits substantiated by clinical research. Nutrition 21 holds more than 30 patents for nutrition products and uses. Nutrition 21's portfolio of health and wellness brands include: Chromax(R), Advanced Memory Formula(TM), Diabetes Essentials(TM), Iceland Health(R) Maximum Strength Omega-3 and Iceland Health(R) Joint Relief. The company also manufactures private label supplements and ingredients for third parties. Nutrition 21 distributes its products nationally through more than 29,000 major food, drug and super center retailers as well as internationally. For more information please visit

Safe Harbor Provision

This press release may contain certain forward-looking statements. The words "believe," "expect," "anticipate" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based largely on the company's current expectations and are subject to a number of risks and uncertainties, including without limitation: the effect of the expiration of patents; regulatory issues; uncertainty in the outcomes of clinical trials; changes in external market factors; changes in the Company's business or growth strategy or an inability to execute its strategy due to changes in its industry or the economy generally; the emergence of new or growing competitors; various other competitive factors; and other risks and uncertainties indicated from time to time in the company's filings with the Securities and Exchange Commission, including its Form 10-K/A for the year ended June 30, 2007. Actual results could differ materially from the results referred to in the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this press release will in fact occur. Additionally, the company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements.

Financial Table on following pages


Condensed Consolidated Balance Sheets

(in thousands)


March 31, 2008 June 30, 2007


Current Assets

Cash, cash equivalents and

short-term Investments $1,581 $3,417

Restricted cash 1,000 ---

Accounts receivable, net 4,792 1,918

Other receivables 419 344

Inventories 1,205 3,945

Prepaid expense and other current

assets 1,449 1,369

Total Current Assets 10,446 10,993

Property and equipment, net 77 64

Patents, trademarks, and other

intangibles, net 1,937 3,271

Other intangibles with indefinite lives 5,379 5,379

Goodwill 15,270 14,715

Other assets 2,058 272

Investments 3,000 ---

Total Assets $38,167 $34,694


Current Liabilities

Short-term borrowings $1,808 $---

Accounts payable 5,507 7,085

Accrued expenses 3,493 1,411

Deferred income 1,444 2,929

Series I convertible preferred

stock 3,162 ---

Long-term debt 2,396 2,342

Deferred income taxes 2,152 2,152

Series I convertible preferred stock --- 2,838

Series J convertible preferred stock 11,221 ---

Total Liabilities 31,183 18,757

Stockholders' Equity 6,984 15,937

Total Liabilities and Stockholders'

Equity $38,167 $34,694


Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)


Three Months Nine Months

Ended Ended

March 31, March 31,

2008 2007 2008 2007

Net sales $10,891 $15,658 35,457 $29,171

Other revenues (71) 107 569 380

TOTAL REVENUES 10,820 15,765 36,026 29,551


Cost of revenues 6,064 4,790 14,056 9,194

Advertising and promotion

expenses 8,568 10,249 28,277 21,933

General and administrative

expenses 2,358 1,052 4,767 4,467

Research and development

expenses 330 259 844 949

Depreciation and amortization 604 962 1,708 2,593

TOTAL COSTS AND EXPENSES 17,924 17,312 49,652 39,136

OPERATING LOSS (7,104) (1,547) (13,626) (9,585)

Interest income 95 115 241 375

Interest expense (1,159) (760) (2,649) (1,766)

LOSS BEFORE INCOME TAXES (8,168) (2,192) (16,034) (10,976)

Income taxes 7 4 13 10

NET LOSS $(8,175) $(2,196) $(16,047) $(10,986)

Basic and diluted loss per

common share $(0.13) $(0.04) $(0.26) $(0.19)

Weighted average number of

common shares - basic

and diluted 62,176,175 59,524,369 61,796,508 56,616,985

Contact: Lytham Partners, LLC

Joe Diaz, Joe Dorame, Robert Blum

(602) 889-9700

SOURCE Nutrition 21, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Better Nutrition Launches 2008 Summer Nutrition Tour
2. SURGEX(TM) Becomes the Official Sports Nutrition Drink of Former NBA Player Dee Brown and his Edge Basketball Training Facility
3. Tom Shaws NFL Training Center Chooses SURGEX(TM) as Their Exclusive Post Training Nutritional Regimen
4. Nutrition 21 to Report Second Quarter Fiscal 2008 Financial Results Monday, February 11, 2008
5. Max Nutrition, Inc. Completes Share Exchange with American Spring Pharmaceutical, Inc.
6. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
7. Natural Nutrition Launches International Marketing Campaign for New All Natural Analgesic: BLUE LIGHTNING(TM) Fast Pain Relief
8. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
9. Salugen Expands U.S. Distribution and Announces a Partnership with DNA Dimensions to Bring DNA Customized Nutritional Solutions to Metro Detroit Area
10. Pilot Therapeutics Announces New Executive Team with Extensive Experience Creating New Health and Nutrition Businesses
11. CNCA Exceeds Standards in Nutritional Supplement Quality, Protects Public
Post Your Comments:
(Date:11/25/2015)... -- Studies reveal the differences in species ... the way for more effective treatment for one of the ... --> --> Gum disease ... cats, yet relatively little was understood about the bacteria associated ... conducted by researchers from the WALTHAM Centre for Pet Nutrition ...
(Date:11/25/2015)... Nov. 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... in a fireside chat discussion at the Piper Jaffray ... . The discussion is scheduled for Wednesday, December ... .  A replay will be available for 14 ... , Julie NormartVP, Corporate Communications and Business Development ...
(Date:11/24/2015)... Nov. 24, 2015 Cepheid (NASDAQ: CPHD ... at the following conference, and invited investors to participate ...      Tuesday, December 1, 2015 at 11.00 a.m. ...      Tuesday, December 1, 2015 at 11.00 a.m. ... New York, NY      Tuesday, December ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
Breaking Biology Technology:
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
(Date:10/29/2015)... 2015  Connected health pioneer, Joseph C. Kvedar ... technology-enabled health and wellness, and the business opportunities that ... The Internet of Healthy Things . Long before ... existed, Dr. Kvedar, vice president, Connected Health, Partners HealthCare, ... moving care from the hospital or doctor,s office into ...
(Date:10/27/2015)... Oct. 27, 2015 Synaptics Inc. (NASDAQ: SYNA ... that Google has adopted the Synaptics ® ClearPad ... to power its newest flagship smartphones, the Nexus 5X ... --> --> Synaptics ... provide strategic collaboration in the joint development of next ...
Breaking Biology News(10 mins):